{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T11:09:47Z","timestamp":1793185787344,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jns.2021.117309","type":"journal-article","created":{"date-parts":[[2021,1,17]],"date-time":"2021-01-17T23:53:25Z","timestamp":1610927605000},"page":"117309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Single-dose L-dopa increases upper brainstem GABA in Parkinson's disease: A preliminary study"],"prefix":"10.1016","volume":"422","author":[{"given":"Yulu","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Mikkelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangbin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.E.","family":"Edden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9423","key":"10.1016\/j.jns.2021.117309_bb0005","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/S0140-6736(04)16305-8","article-title":"Parkinson\u2019s disease","volume":"363","author":"Samii","year":"2004","journal-title":"Lancet"},{"issue":"9996","key":"10.1016\/j.jns.2021.117309_bb0010","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson's disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"issue":"Suppl. 3","key":"10.1016\/j.jns.2021.117309_bb0015","doi-asserted-by":"crossref","first-page":"S497","DOI":"10.1002\/mds.22028","article-title":"The history of dopamine and levodopa in the treatment of Parkinson\u2019s disease","volume":"23","author":"Fahn","year":"2008","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.jns.2021.117309_bb0020","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson\u2019s disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol. Aging"},{"issue":"5","key":"10.1016\/j.jns.2021.117309_bb0025","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1152\/jn.1989.62.5.1018","article-title":"GABA as an inhibitory neurotransmitter in human cerebral cortex","volume":"62","author":"McCormick","year":"1989","journal-title":"J. Neurophysiol."},{"issue":"3\u20134","key":"10.1016\/j.jns.2021.117309_bb0030","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0014-2999(84)90635-6","article-title":"A physiological role for dopamine as modulator of GABA effects in substantia nigra: supersensitivity in 6-hydroxydopamine-lesioned rats","volume":"105","author":"Waszczak","year":"1984","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jns.2021.117309_bb0035","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.bbr.2015.04.018","article-title":"Basal ganglia circuit loops, dopamine and motivation: a review and enquiry","volume":"290","author":"Ikemoto","year":"2015","journal-title":"Behav. Brain Res."},{"issue":"7","key":"10.1016\/j.jns.2021.117309_bb0040","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0166-2236(90)90110-V","article-title":"Primate models of movement disorders of basal ganglia origin","volume":"13","author":"DeLong","year":"1990","journal-title":"Trends Neurosci."},{"issue":"2","key":"10.1016\/j.jns.2021.117309_bb0045","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.yfrne.2013.03.001","article-title":"Neurosteroid and neurotransmitter alterations in Parkinson\u2019s disease","volume":"34","author":"di Michele","year":"2013","journal-title":"Front. Neuroendocrinol."},{"issue":"5","key":"10.1016\/j.jns.2021.117309_bb0050","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/jmri.24665","article-title":"Decreased gamma-aminobutyric acid levels in the parietal region of patients with Alzheimer\u2019s disease","volume":"41","author":"Bai","year":"2015","journal-title":"J. Magn. Reson. Imaging"},{"issue":"3","key":"10.1016\/j.jns.2021.117309_bb0055","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s11604-017-0714-z","article-title":"Examining alterations in GABA concentrations in the basal ganglia of patients with Parkinson\u2019s disease using MEGA-PRESS MRS","volume":"36","author":"Elmaki","year":"2018","journal-title":"Jpn. J. Radiol."},{"issue":"1","key":"10.1016\/j.jns.2021.117309_bb0060","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12868-019-0522-8","article-title":"Comparative study of striatum GABA concentrations and magnetic resonance spectroscopic imaging in Parkinson\u2019s disease monkeys","volume":"20","author":"Huang","year":"2019","journal-title":"BMC Neurosci."},{"issue":"6","key":"10.1016\/j.jns.2021.117309_bb0065","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1002\/jmri.25865","article-title":"Inhibitory motor dysfunction in parkinson\u2019s disease subtypes","volume":"47","author":"Gong","year":"2018","journal-title":"J. Magn. Reson. Imaging"},{"key":"10.1016\/j.jns.2021.117309_bb0070","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.neuroimage.2012.12.004","article-title":"Current practice in the use of MEGA-PRESS spectroscopy for the detection of GABA","volume":"86","author":"Mullins","year":"2014","journal-title":"Neuroimage"},{"issue":"6","key":"10.1016\/j.jns.2021.117309_bb0075","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/(SICI)1099-1492(199810)11:6<266::AID-NBM530>3.0.CO;2-J","article-title":"Simultaneous in vivo spectral editing and water suppression","volume":"11","author":"Mescher","year":"1998","journal-title":"NMR Biomed."},{"key":"10.1016\/j.jns.2021.117309_bb0080","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.neuroimage.2017.07.021","article-title":"Big GABA: edited MR spectroscopy at 24 research sites","volume":"159","author":"Mikkelsen","year":"2017","journal-title":"Neuroimage"},{"issue":"14","key":"10.1016\/j.jns.2021.117309_bb0085","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.18632\/aging.102095","article-title":"Ginsenoside Rb1 regulates prefrontal cortical GABAergic transmission in MPTP-treated mice","volume":"11","author":"Liu","year":"2019","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"10.1016\/j.jns.2021.117309_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030918","article-title":"Elevated pontine and putamenal GABA levels in mild-moderate Parkinson disease detected by 7 tesla proton MRS","volume":"7","author":"Emir","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jns.2021.117309_bb0095","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/mrm.20761","article-title":"Proton MRS of the unilateral substantia nigra in the human brain at 4 tesla: detection of high GABA concentrations","volume":"55","author":"Oz","year":"2006","journal-title":"Magn. Reson. Med."},{"key":"10.1016\/j.jns.2021.117309_bb0100","doi-asserted-by":"crossref","first-page":"806","DOI":"10.3389\/fneur.2018.00806","article-title":"Beyond Dopamine: GABA, glutamate, and the axial symptoms of Parkinson Disease","volume":"9","author":"O\u2019Gorman Tuura","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jns.2021.117309_bb0105","first-page":"11(813)","article-title":"Feasibility of measuring GABA levels in the upper brainstem in healthy volunteers using edited MRS","author":"Song","year":"2020","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.jns.2021.117309_bb0110","article-title":"Levodopa challenge test: indications, protocol, and guide","author":"Saranza","year":"2020","journal-title":"J. Neurol."},{"issue":"6","key":"10.1016\/j.jns.2021.117309_bb0115","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1002\/jmri.24478","article-title":"Gannet: a batch-processing tool for the quantitative analysis of gamma-aminobutyric acid-edited MR spectroscopy spectra","volume":"40","author":"Edden","year":"2014","journal-title":"J. Magn. Reson. Imaging"},{"issue":"1","key":"10.1016\/j.jns.2021.117309_bb0120","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/mrm.25094","article-title":"Frequency and phase drift correction of magnetic resonance spectroscopy data by spectral registration in the time domain","volume":"73","author":"Near","year":"2015","journal-title":"Magn. Reson. Med."},{"issue":"2","key":"10.1016\/j.jns.2021.117309_bb0125","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1148\/radiology.211.2.r99ma53489","article-title":"T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation to iron content","volume":"211","author":"Vymazal","year":"1999","journal-title":"Radiology"},{"key":"10.1016\/j.jns.2021.117309_bb0130","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.neuroimage.2013.08.051","article-title":"Reversible, irreversible and effective transverse relaxation rates in normal aging brain at 3T","volume":"84","author":"Sedlacik","year":"2014","journal-title":"Neuroimage"},{"key":"10.1016\/j.jns.2021.117309_bb0135","first-page":"958","article-title":"3D-Relaxometry -Quantitative T1 and T2 Brain Mapping at 3T","volume":"14","author":"M\u00e4dler","year":"2006","journal-title":"Proc. Int. Soc. Magn. Reson. Med."},{"issue":"6","key":"10.1016\/j.jns.2021.117309_bb0140","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/mrm.20901","article-title":"Use of tissue water as a concentration reference for proton spectroscopic imaging","volume":"55","author":"Gasparovic","year":"2006","journal-title":"Magn. Reson. Med."},{"issue":"1","key":"10.1016\/j.jns.2021.117309_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/jmrb.1993.1055","article-title":"Absolute quantitation of water and metabolites in the human brain I compartments and water","volume":"102","author":"Ernst","year":"1993","journal-title":"J. Magn. Reson."},{"issue":"4","key":"10.1016\/j.jns.2021.117309_bb0150","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1185\/030079902125000741","article-title":"Choosing the right dopamine agonist for patients with Parkinson\u2019s disease","volume":"18","author":"Lebrun-Frenay","year":"2002","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jns.2021.117309_bb0155","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/B978-0-12-386467-3.00004-2","article-title":"The pharmacology of selegiline","volume":"100","author":"Magyar","year":"2011","journal-title":"Int. Rev. Neurobiol."},{"issue":"4","key":"10.1016\/j.jns.2021.117309_bb0160","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/1531-8257(199907)14:4<572::AID-MDS1005>3.0.CO;2-C","article-title":"Core assessment program for surgical interventional therapies in Parkinson\u2019s disease (CAPSIT-PD)","volume":"14","author":"Defer","year":"1999","journal-title":"Mov. Disord."},{"issue":"7419","key":"10.1016\/j.jns.2021.117309_bb0165","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nature11466","article-title":"Dopaminergic neurons inhibit striatal output through non-canonical release of GABA","volume":"490","author":"Tritsch","year":"2012","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.jns.2021.117309_bb0170","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrn.2015.21","article-title":"Mechanisms and functions of GABA co-release","volume":"17","author":"Tritsch","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.jns.2021.117309_bb0175","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.01936","article-title":"Midbrain dopamine neurons sustain inhibitory transmission using plasma membrane uptake of GABA, not synthesis","volume":"3","author":"Tritsch","year":"2014","journal-title":"Elife"},{"issue":"3","key":"10.1016\/j.jns.2021.117309_bb0180","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1239","article-title":"Attenuation of dopamine-induced GABA release in problem gamblers","volume":"9","author":"Moller","year":"2019","journal-title":"Brain Behav."},{"issue":"6","key":"10.1016\/j.jns.2021.117309_bb0185","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/j.1471-4159.2011.07376.x","article-title":"Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels","volume":"118","author":"Bido","year":"2011","journal-title":"J. Neurochem."},{"issue":"2","key":"10.1016\/j.jns.2021.117309_bb0190","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/syn.20006","article-title":"L-DOPA-induced modulation of GABA and glutamate release in substantia nigra pars reticulata in a rodent model of Parkinson\u2019s disease","volume":"52","author":"Ochi","year":"2004","journal-title":"Synapse"},{"issue":"7","key":"10.1016\/j.jns.2021.117309_bb0195","doi-asserted-by":"crossref","first-page":"e675","DOI":"10.1212\/WNL.0000000000006007","article-title":"Reduced occipital GABA in Parkinson disease with visual hallucinations","volume":"91","author":"Firbank","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2021.117309_bb0200","first-page":"8(2)","article-title":"Impairment of Motor Function Correlates with Neurometabolite and Brain Iron Alterations in Parkinson's Disease","author":"Pesch","year":"2019","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.jns.2021.117309_bb0205","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/hbm.24857","article-title":"GABAergic changes in the thalamocortical circuit in Parkinson\u2019s disease","volume":"41","author":"van Nuland","year":"2020","journal-title":"Hum. Brain Mapp."},{"key":"10.1016\/j.jns.2021.117309_bb0210","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.neuroimage.2015.06.066","article-title":"Striatal and thalamic GABA level concentrations play differential roles for the modulation of response selection processes by proprioceptive information","volume":"120","author":"Dharmadhikari","year":"2015","journal-title":"Neuroimage"},{"key":"10.1016\/j.jns.2021.117309_bb0215","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.parkreldis.2018.02.014","article-title":"Neurotransmitter activity is linked to outcome following subthalamic deep brain stimulation in Parkinson\u2019s disease","volume":"50","author":"O\u2019Gorman Tuura","year":"2018","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jns.2021.117309_bb0220","doi-asserted-by":"crossref","DOI":"10.1002\/mds.28221","article-title":"High gamma-aminobutyric acid content within the medial prefrontal cortex is a functional signature of somatic symptoms disorder in patients with Parkinson\u2019s disease","author":"Delli Pizzi","year":"2020","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.jns.2021.117309_bb0225","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pneurobio.2006.12.003","article-title":"N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology","volume":"81","author":"Moffett","year":"2007","journal-title":"Prog. Neurobiol."},{"issue":"3","key":"10.1016\/j.jns.2021.117309_bb0230","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.parkreldis.2012.11.012","article-title":"Marked N-acetylaspartate and choline metabolite changes in Parkinson\u2019s disease patients with mild cognitive impairment","volume":"19","author":"Nie","year":"2013","journal-title":"Parkinsonism Relat. Disord."},{"issue":"9","key":"10.1016\/j.jns.2021.117309_bb0235","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.792","article-title":"Detection and application of neurochemical profile by multiple regional (1)H-MRS in Parkinson's disease","volume":"7","author":"Guan","year":"2017","journal-title":"Brain Behav."},{"issue":"1","key":"10.1016\/j.jns.2021.117309_bb0240","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11682-013-9251-2","article-title":"Application of proton magnetic resonance spectroscopy on substantia nigra metabolites in Parkinson's disease","volume":"8","author":"Zhou","year":"2014","journal-title":"Brain Imag. Behav."},{"key":"10.1016\/j.jns.2021.117309_bb0245","first-page":"30(2)","article-title":"Neurometabolic profiles of the substantia nigra and striatum of MPTP-intoxicated common marmosets: An in vivo proton MRS study at 9.4 T","author":"Heo","year":"2017","journal-title":"NMR Biomed."},{"key":"10.1016\/j.jns.2021.117309_bb0250","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.neulet.2017.08.050","article-title":"Evaluation of the Braak staging of brain pathology with (1)H-MRS in patients with Parkinson\u2019s disease","volume":"660","author":"Cao","year":"2017","journal-title":"Neurosci. Lett."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X21000022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X21000022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:53:01Z","timestamp":1758383581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X21000022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":50,"alternative-id":["S0022510X21000022"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2021.117309","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single-dose L-dopa increases upper brainstem GABA in Parkinson's disease: A preliminary study","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2021.117309","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117309"}}